Navigation Links
Medivation Announces Second Quarter 2009 Financial Results Teleconference and Webcast on August 5, 2009
Date:7/29/2009

SAN FRANCISCO, July 29 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss second quarter 2009 financial results and provide a general business update on Wednesday, August 5, 2009, at 4:30 p.m. Eastern Time. A press release for the second quarter ended June 30, 2009 will be released after markets close on August 5, 2009.

Interested parties may call 888-287-5532 from the U.S. or +1-719-325-2124 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, the Company is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate and severe Alzheimer's disease. Further development of dimebon in patients with Huntington disease is also planned. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing, and a Phase 3 trial is expected to begin this year. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medivation to Present at 8th Annual Needham Life Sciences Conference
2. Medivation Announces Offering of 2,750,000 Shares of Common Stock
3. Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
4. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
5. Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
6. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
7. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
8. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
9. Medivation Announces Participation in Upcoming Conferences
10. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
11. Medivation Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... Global ... diseases through research, education and awareness, today announced the appointment of Timothy J. ... microbiologist, Dr. Sellati has more than 20 years of research experience with Lyme ...
(Date:9/21/2017)... ... September 21, 2017 , ... SABRE is raising awareness about personal ... to the end of November. , The Chicago, Illinois, based self-defense brand has been ... them about the ease of taking their personal safety into their own hands. , ...
(Date:9/21/2017)... Virginia (PRWEB) , ... September 21, 2017 , ... ... health in their communities, nine governmental public health departments have been awarded five-year ... accreditation decisions mean that the benefits of being served by a PHAB-accredited ...
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center for Children® ... the election of Yie-Hsin Hung to the Board of Directors. , “The New ... Directors. Ms. Hung is an invaluable addition to our team,” said Vincent Strully, Jr., ...
(Date:9/21/2017)... ... ... FlipBelt, the fitness brand that specializes in problem solving fitness accessories, has ... the launch of their FlipBelt Crops. , The new fitness bottoms feature an integrated ... at the gym, on the trail, or on-the-go. , “We always thought the FlipBelt ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... Sept. 8, 2017 Dealmed Medical Supplies, ... of medical equipment, supplies, drugs, vaccines, and specialty medical ... into an agreement to acquire Vantage Medical Supplies, a ... Holtsville, New York . ... new and emerging medical practices, will operate under the ...
(Date:9/7/2017)... Sept. 7, 2017  Eli Lilly and Company ... to streamline operations to more efficiently focus resources ... cost structure. Global workforce reductions, including those from ... to impact approximately 3,500 positions. ... annualized savings of approximately $500 million that will ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris ... focused on fulfilling the promise of precision medicine, ... validate the benefits of its molecular profiling approach ... utilized comprehensive genomic profiling plus (CGP+) with Caris ... patient,s tumor on a molecular level, leading to ...
Breaking Medicine Technology: